Cost of treating HIV remains high; Louisiana feels the pain

Daugherty, Christi
December 1998
New Orleans CityBusiness (1994 to 2008);12/14/98, Vol. 19 Issue 24, p25
Reports on the rise of drug therapy costs for HIV infection in Louisiana. Insurance coverage of patients with HIV; Average expenses of patients with HIV or AIDS; Reasons for the increase of HIV drug therapy costs; Effects of drug therapy to people with HIV.


Related Articles

  • Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy. Anis, A.H.; Hogg, R.S.; Wang, X-h.; Yip, B.; Palepu, A.; Montaner, J.S.G.; O’Shaughnessy, M.V.; Schechter, M.T.; Montaner, J S; O'Shaughnessy, M V // PharmacoEconomics;1998, Vol. 13 Issue 6, p697 

    The purpose of this study is to model the potential economic impact of viral load-driven triple drug combination (including a protease inhibitor) antiretroviral therapy on incremental drug and hospitalisation costs among individuals with HIV disease. Individuals included in the study were...

  • Non-Adherence to Anti-Tuberculosis Treatment and Determinant Factors among Patients with Tuberculosis in Northwest Ethiopia. Adane, Akilew Awoke; Alene, Kefyalew Addis; Koye, Digsu Negese; Zeleke, Berihun Megabiaw // PLoS ONE;Nov2013, Vol. 8 Issue 11, p1 

    Background: Non-adherence to anti tuberculosis treatment is one of the crucial challenges in improving tuberculosis cure-rates and reducing further healthcare costs. The poor adherence to anti-tuberculosis treatment among patients with tuberculosis is a major problem in Ethiopia. Hence, this...

  • Financing Health Care for Persons with HIV Infection: Guidelines for State Action. Fox, Daniel M. // American Journal of Law & Medicine;1990, Vol. 16 Issue 1/2, p223 

    Promises of confidentiality of HIV-related medical records and protection from discrimination based on HIV seropositivity are two of the legislative inducements state governments have offered to encourage voluntary HIV testing. Yet neither can be granted without impact on others whose interests...

  • Resistance, remission, and qualitative differences in HIV chemotherapy. Kirschner, Denise E.; Webb, G.F. // Emerging Infectious Diseases;Jul-Sep97, Vol. 3 Issue 3, p273 

    Presents a design of a mathematical system that models human immunodeficiency virus (HIV) multidrug chemotherapy including uninfected and infected CD4+T cells and virus population. Inclusions in the model; Indications from the simulations; Important distinction between resistance and remission;...

  • First of a new class of drugs for HIV.  // Modern Medicine;Feb96, Vol. 64 Issue 2, p38 

    Reports on the United States Food and Drug Administration's approval of the drug Saquinavir mesylate (Invirase), indicated for HIV infections. Mode of action.

  • First-line treatment of HIV infection.  // Modern Medicine;Nov96, Vol. 64 Issue 11, p33 

    Reports on the Food and Drug Administration's approval of Didanosine as a monotherapy for treating HIV infection when antiretroviral therapy is warranted.

  • Prescriptions pile up for AIDS combination therapy. Rodgers, Katie // Drug Topics;1/8/96, Vol. 140 Issue 1, p14 

    Reports on developments related to chemotherapy for advanced HIV infection. Includes the US Food & Drug Administration's approval of saquinavir protease inhibitor; Combination therapy with nucleoside analogs; Prescriptions for lamivudine.

  • High hopes. McCann, Jean // Drug Topics;Aug96, Vol. 140 Issue 15, p54 

    Reports that AIDS researchers are talking about turning HIV disease from an ultimately fatal infection into a chronic disease that can be controlled by chronic therapy. Findings on the effect of triple-drug therapy on HIV; Comparison of HIV infection to a raging fire; Treatment of patients with...

  • Dosing guidelines for foscarnet and trimetrexate.  // Formulary;Jun95, Vol. 30 Issue 6, p349 

    Presents dosing and monitoring guidelines for foscarnet sodium and trimetrexate glucuronate used to treat patients with opportunistic infections associated with HIV infection. Guidelines by the P & T Committee at the Trinity Lutheran Hospital in Kansas City, Missouri; Discussion of drugs;...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics